SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ViroLogic (VLGC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Knowlton who wrote (19)8/29/2000 1:52:18 PM
From: Ian@SI  Read Replies (1) of 59
 
Don,

Yes, the numbers I used to calculate potential daily/annual revenues are conservative relative to the article.

I think they put a reasonable range on the revenue that could be expected if, and once, the planned capacity is used. i.e. - by the end of this year, sufficient capacity will be in place to support a runrate of about $50M to $60M or about a 15% to 20% share of the market.

Another potential upside comes from the increasing number of drugs entering the marketplace to treat AIDS. As more drugs are screened for resistance, we can expect increased revenues to accrue to VLGC.

I am quite enthused with this company's upside potential.

Hope you're able to find a profitable entry point.

Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News